Andrés Ignacio Nuñez Salinas

Prof. Andrés Ignacio Nuñez Salinas

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Andrés Ignacio Nuñez SalinasAndrés Ignacio Nuñez Salinas
Andrés Ignacio Nuñez Salinas
CPCristian Parra-Garretón
Cristian Parra-Garretón
DADaniel Acuña
Daniel Acuña
SPSofía Peñaloza
Sofía Peñaloza
GGGerman Gunther
German Gunther
JMJavier Morales
Javier Morales
Nanoradiopharmaceuticals integrate nanotechnology with nuclear medicine to enhance the precision and effectiveness of radiopharmaceuticals used in diagnostic imaging and targeted therapies. Nanomaterials offer improved targeting capabilities and greater stability, helping to overcome several limitations. This review presents a comprehensive overview of the fundamental design principles, radiolabeling techniques, and biomedical applications of nanoradiopharmaceuticals, with a particular focus on their expanding role in precision oncology. It explores key areas, including single- and multi-modal imaging modalities (SPECT, PET), radionuclide therapies involving beta, alpha, and Auger emitters, and integrated theranostic systems. A diverse array of nanocarriers is examined, including liposomes, micelles, albumin nanoparticles, PLGA, dendrimers, and gold, iron oxide, and silica-based platforms, with an assessment of both preclinical and clinical research outcomes. Theranostic nanoplatforms, which integrate diagnostic and therapeutic functions within a single system, enable real-time monitoring and personalized dose optimization. Although some of these systems have progressed to clinical trials, several obstacles remain, including formulation stability, scalable manufacturing, regulatory compliance, and long-term safety considerations. In summary, nanoradiopharmaceuticals represent a promising frontier in personalized medicine, particularly in oncology. By combining diagnostic and therapeutic capabilities within a single nanosystem, they facilitate more individualized and adaptive treatment approaches. Continued innovation in formulation, radiochemistry, and regulatory harmonization will be crucial to their successful routine clinical use.

1 January 2010 in Journal of the Brazilian Chemical Society
Verified
Journal Article
Open access
PDF file
CPCarlos David Pessoa-Mahana
Carlos David Pessoa-Mahana
Andrés Ignacio Nuñez SalinasAndrés Ignacio Nuñez Salinas
Andrés Ignacio Nuñez Salinas
Christian Espinosa-BustosChristian Espinosa-Bustos
Christian Espinosa-Bustos
Jaime Mella-RaipánJaime Mella-Raipán
Jaime Mella-Raipán
HPHernán Pessoa-Mahana
Hernán Pessoa-Mahana
The synthesis of a series of substituted arylpiperazines linked to a 2-(pyridin-3-yl)-1H-benzo[d]imidazole scaffold through an alkylic linker is reported. The novel 1-(2-(4-arylpiperazin-1-yl)alkyl)-2-(pyridin-3-yl)-1H-benzimidazole derivatives are structurally related to the anti-HIV-1 drug Delavirdine and belong to the bis(heteroaryl)piperazines family (BHAPs), a well known HIV-1 reverse transcriptase inhibitors group.

6 May 2026 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
SPSofía Peñaloza
Sofía Peñaloza
RRRodrigo Rozas
Rodrigo Rozas
Andrés Ignacio Nuñez SalinasAndrés Ignacio Nuñez Salinas
Andrés Ignacio Nuñez Salinas
RPRodrigo Pérez
Rodrigo Pérez
AOAndrea C. Ortiz
Andrea C. Ortiz
Francisco ArriagadaFrancisco Arriagada
Francisco Arriagada